Youth Metacognitive Therapy Feasibility Trial (YoMETA)

University of Manchester

Status: Completed

Conditions: Depression; Anxiety Disorders; Child Mental Disorder

Treatments: Behavioral: Group Metacognitive Therapy (Group-MCT): Experimental; Behavioral: Treatment as usual: Control

Study type: Interventional

Funder types: Other

Identifiers

NCT05260060

IRAS ID: 296079

Details and patient eligibility

About

One in eight children and young people (CYP) suffer mental health problems needing support or treatment and 5% have more than one such problem. The effects can be major, affecting CYP emotionally and functionally, impacting progress at school, relationships with others and increasing long term risk of mental health problems. Parents, schools, policy makers and the NHS often struggle to find the best way to help, especially within their limited budgets. The UK Government and the NHS have highlighted the need to improve mental health in CYP.

The most common treatment is cognitive behavioural therapy; however this can be time consuming, needs to be delivered over many weeks, must focus on the most upsetting problem first and is not very effective. One way to overcome this is to evaluate a group therapy that can treat multiple mental health problems at once. This new treatment is called Metacognitive Therapy (MCT).

The aim of the study is to see if participating in a randomized trial of Group MCT is a feasible and acceptable treatment for CYP suffering with anxiety, stress, depression, or a combination in comparison to usual care. This allows us to test key questions about recruitment and drop-out rates, test the protocol, and gain information about MCT including training and supervision needs of clinicians and the experience of patients receiving it.

Enrollment: 95 patients

Sex: All

Ages: 11 to 16 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Seeking treatment for emotional disorder symptoms (i.e. generalized anxiety disorder, panic disorder, agoraphobia, post-traumatic stress disorder, obsessive compulsive disorder, social anxiety and/or depression).
• Native fluency in English language
• Medication permitted but must be stabilised for 6 weeks.

Exclusion criteria

• Presence of significant risk or safeguarding concerns
• Head injury/organic impairment
• Formal diagnosis or under assessment for Autism Spectrum Disorder or Attention Deficit-Hyperactivity Disorder
• Eating Disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

95 participants in 2 patient groups

Usual Treatment (Control)

Active Comparator group

Description:

Participants allocated to the control group will receive treatment as usual under the child and adolescent mental health service.

Treatment:

Behavioral: Treatment as usual: Control

Group MCT (Intervention)

Experimental group

Description:

Participants allocated to the intervention group will receive group metacognitive therapy sessions.

Treatment:

Behavioral: Group Metacognitive Therapy (Group-MCT): Experimental